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Objective. To assess candidate genes for associa-
tion with osteoarthritis (OA) and identify promising
genetic factors and, secondarily, to assess the candidate
gene approach in OA.
Methods. A total of 199 candidate genes for
association with OA were identified using Human Ge-
nome Epidemiology (HuGE) Navigator. All of their
single-nucleotide polymorphisms (SNPs) with an allele
frequency of >5% were assessed by fixed-effects meta-
analysis of 9 genome-wide association studies (GWAS)
that included 5,636 patients with knee OA and 16,972
control subjects and 4,349 patients with hip OA and
17,836 control subjects of European ancestry. An addi-
tional 5,921 individuals were genotyped for significantly
associated SNPs in the meta-analysis. After correction
for the number of independent tests, P values less than
1.58  105 were considered significant.
Results. SNPs at only 2 of the 199 candidate genes
(COL11A1 and VEGF) were associated with OA in the
meta-analysis. Two SNPs in COL11A1 showed associa-
tion with hip OA in the combined analysis: rs4907986
(P  1.29  105, odds ratio [OR] 1.12, 95% confidence
interval [95% CI] 1.061.17) and rs1241164 (P 
1.47  105, OR 0.82, 95% CI 0.740.89). The sex-
stratified analysis also showed association of COL11A1
SNP rs4908291 in women (P  1.29  105, OR 0.87,
95% CI 0.820.92); this SNP showed linkage disequili-
brium with rs4907986. A single SNP of VEGF, rs833058,
showed association with hip OA in men (P  1.35 
105, OR 0.85, 95% CI 0.790.91). After additional
samples were genotyped, association at one of the
COL11A1 signals was reinforced, whereas association at
VEGF was slightly weakened.
Conclusion. Two candidate genes, COL11A1 and
VEGF, were significantly associated with OA in this
focused meta-analysis. The remaining candidate genes
were not associated.
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The etiology of primary osteoarthritis (OA) is
multifactorial and includes aging and mechanical, hor-
monal, and genetic factors (1). Investigations of many of
these factors have produced contradictory results, mak-
ing conclusions difficult. Some of the contradictory
results are attributable to the design of the studies, but
others can be attributable to undetermined differences
between patients (1,2). It is also notable that suscepti-
bility factors, including genetic factors, are not equally
shared by the different joint regions affected by OA
(3,4).
Previous attempts have been made to identify
genetic factors involved in OA, using association studies
of candidate genes, linkage studies in multicase families,
or genome-wide association studies (GWAS) (2,5). Can-
didate genes were studied because of their important
roles in the pathogenesis of OA or their altered expres-
sion in OA tissue. The results of most of these associa-
tion studies have been inconclusive. The association of
only one candidate gene, GDF5, was well supported by
data from multiple studies and reached genome-wide
significance (P  5  108) in subsequent replication
analysis (6,7). Linkage studies have provided some con-
sistent results, but progression from these results to
identification of the causal genes has proven to be
difficult (2,5).
Recently, GWAS have identified 11 additional
OA susceptibility loci with genome-wide significance
levels. Two of them, in DVWA/COL6A4 and a region
containing HLA class II/III genes, showed association in
Asians but not in Europeans (8–10). The other 9 loci
reached genome-wide significance in Europeans. They
include a locus on chromosome 7q22 (which is located in
a large linkage disequilibrium [LD] block that contains
6 genes) associated with knee OA (11,12); MCF2L
associated with knee and hip OA (13); 5 loci that were
identified in the arcOGEN GWAS (GNL3/GLT8D1
associated with knee and hip OA, ASTN2 associated
with severe hip OA in women, FILIP1–SENP6 and
PTHLH associated with hip OA, and CHTS11 associated
with severe hip OA) (14); and DOT1L associated with
joint space width of the hip (15) and with hip OA in men
(16). Approximately 8 more loci are near this level of
association (2,5,14).
All of the studies reaching genome-wide signifi-
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cance have used meta-analysis of data from multiple
sample collections. This is a very efficient approach to
increase power. In addition, it is also very useful for
discovery of new associations when applied to GWAS,
because each study provides information for most single-
nucleotide polymorphisms (SNPs) in the genome, either
directly or through imputation, and therefore add to the
overall result (17). Another way to favor discovery of
new loci is by focusing analysis on particular subsets of
genes for which there is prior supporting evidence,
thereby increasing the prior probability of association
and reducing the burden of multiplicity and thus the
stringency required for claiming association (18,19).
The aim of this study was to identify new OA
genetic factors, using meta-analysis of GWAS and fo-
cused analysis of OA candidate genes. A secondary aim
was to assess the validity of the candidate gene approach
in OA. To this end, we performed a meta-analysis of
5,636 patients with knee OA and 4,349 patients with hip
OA from 9 GWAS and explored the association with
knee OA or hip OA with 24,000 SNPs corresponding
to 199 previously reported OA candidate genes. Two
candidate genes, COL11A1 and VEGF, were signifi-
cantly associated with OA. The remaining 197 candidate
genes were not significantly associated with OA.
PATIENTS AND METHODS
Sample collections. We performed a meta-analysis of 9
GWAS that included patients with knee or hip OA and control
subjects of European descent: the deCODE study from Ice-
land (20), 3 collections from the Rotterdam Study (Rotterdam
Study I, II, and III) (21), the Genetics Osteoarthritis and
Progression (GARP) collection from The Netherlands (22),
arcOGEN phase I (23) and TwinsUK (24) from the UK, the
Framingham Osteoarthritis Study from the US (25), and
EGCUT (Estonian Genome Center of the University of Tartu)
from Estonia (26). Additional sample collections not involved
in the GWAS were used for an extension study of significant
results (Table 1). They included collections from the north of
Spain (27–29), the center of Greece (30), and the Nottingham
(31) and Genetics in Osteoarthritis and Lifestyle (GOAL) (32)
studies from the UK.
All of these sample collections have been described in
detail previously. Briefly, the deCODE study included patients
with total knee replacement or total hip replacement, patients
with OA, and population controls, which excluded all individ-
uals on OA susceptibility lists (hand, hip, knee) obtained from
hospitals and health care centers in Iceland (20). The Rotter-
dam Study, Framingham Osteoarthritis Study, and TwinsUK
included patients with radiographic OA and controls from the
same cohort without radiographic signs of OA, as defined
according to standardized phenotypes, with patients having a
Kellgren/Lawrence (K/L) score (33) of 2 and controls having
a K/L score of 2 (34). The GARP cohort included patients
with confirmed clinical and radiographic (K/L score of2) OA
Table 1. Characteristics of the sample collections included in the GWAS meta-analysis and the
extension study*
Knee OA Hip OA
OA definitionCases Controls Cases Controls
Meta-analysis
arcOGEN study 1,643 4,896 1,728 4,896 TJR and radiographic
deCODE study† 1,312 2,318 1,423 2,318 TJR and clinical
Framingham study 417 1,667 NA Radiographic
GARP study 154 1,671 106 1,671 Radiographic and clinical
Rotterdam Study I 1,476 3,233 760 3,233 Radiographic
Rotterdam Study II 369 1,472 159 1,472 Radiographic
Rotterdam Study III 152 1,487 41 1,487 Radiographic
TwinsUK 113 228 68 228 Radiographic
EGCUT study 64 2,531 Radiographic
Total 5,636 16,972 4,349 17,836 –
Extension study
Spain‡ – – 695 784 TJR
Greece – – 92 358 TJR
Nottingham§ – – 1,246 713 TJR
GOAL§ – – 1,270 763 TJR and radiographic
Total 3,303 2,618 –
* GWAS  genome-wide association study; OA  osteoarthritis; arcOGEN  Arthritis Research UK
Osteoarthritis Genetics; TJR  total joint replacement; NA  not available; GARP  Genetics
Osteoarthritis and Progression; EGCUT Estonian Genome Center of the University of Tartu; GOAL
Genetics in Osteoarthritis and Lifestyle.
† Effective sample size.
‡ Samples were obtained from 3 collections (Santiago, Santander, and A Corunna).
§ Samples were genotyped only for rs833058 (VEGF).
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at 2 joint sites (22). They were compared with population
controls. The arcOGEN phase I cohort included cases of knee
or hip OA, as determined by radiographic evidence of disease
or clinical evidence of disease “to a level requiring joint
replacement” (23); controls were derived from an early release
of the Wellcome Trust Case Control Consortium 2 data.
EGCUT included cases of radiographically confirmed OA
(K/L score of 2) and controls that were free of any OA
symptoms. All sample collections used for the extension study
were derived from casecontrol studies. Patients were ascer-
tained on the basis of having undergone hip joint replacement
due to symptomatic and radiographically confirmed hip OA,
except in GOAL, in which severe symptomatic hip OA was the
selection criterion. All of the sample collections and the
genetic studies received approval by the relevant ethics com-
mittees, and the samples were obtained with the written
informed consent of the participants.
Gene and SNP selection. We used the Phenopedia tool
of the Human Genome Epidemiology (HuGE) Navigator (35)
to identify candidate genes that have been studied for their
possible association with OA, without additional filtering. The
query terms were as follows: osteoarthritis, spinal osteophyto-
sis, and intervertebral disk displacement. The candidate genes
derived from the spinal osteophytosis and intervertebral disk
displacement lists showed a large degree of overlap with those
from the osteoarthritis list (90% and 72%, respectively). The
17 nonoverlapping genes were considered to be of interest for
the discovery of new OA loci. This database covers genetic
studies published since 2000. Genes in chromosome X were
excluded, because it is impossible to impute the genotypes
needed for meta-analysis across different GWAS designs.
FRAH1H was excluded because the bibliographic reference
was incorrect. All of the genes with genome-wide significance
in Europeans (P  5  108) were also excluded. Duplicates
were removed.
Map positions of loci encompassing the candidate
genes and 50 kb downstream of their stop codon and upstream
of their start codon were obtained from the Ensembl database.
Overlapping loci were fused as a single locus. All SNPs with a
minor allele frequency (MAF) of 5% in the CEU data set
corresponding to the candidate gene loci were retrieved from
HapMap (phases 1, 2, and 3; release 27) with in-house Perl
programs interacting with the HapMart server. All SNPs were
aligned according to the positive strand, to avoid ambiguities.
Genotyping and imputation of untyped SNPs. Geno-
typing technologies for the GWAS included in the meta-
analysis were different and have been previously described
in detail (11,20,23,25,36). Imputation of untyped SNPs was
performed based on CEU data from HapMap (phases 1 and
2; release 22). Summary information on genotyping and im-
putation is shown in Supplementary Table 1 (available on the
Arthritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.38300/abstract). Genotyping of the exten-
sion study collections was performed at Hospital Clinico
Universitario de Santiago, using single-base extension with a
SNaPshot Multiplex Kit (Applied Biosystems) (Spanish and
Greek collections) or was carried out by KBioscience, using a
KASPar system (UK collections).
Statistical analysis. Each team contributing a GWAS
performed association testing for knee OA and hip OA under
a per-allele model. The lambda inflation factor was calculated
per sex-specific effect size using the genomic control method
(37), and the SEs were corrected by the square root of the
lambda inflation factor (SEcorrected  SEobserved  ). Robust
SEs were estimated to adjust for family relationships (de-
CODE and GARP studies). For meta-analysis, the effect size
for each SNP (odds ratio [OR] per copy of minor allele as per
HapMap) was calculated using fixed-effects inverse variance
models, synthesizing all effect sizes and the corrected SEs.
Heterogeneity was assessed with the I2 statistic; when
low or moderate heterogeneity was observed, no random-
effects meta-analysis was performed (38). Meta-analysis of
the GWAS was performed using METAL software (39),
considering 6 strata with 2 joint levels (knee and hip) and 3 sex
levels (all, women, and men). Two research centers (Ioannina,
Greece and Erasmus MC Rotterdam, The Netherlands) per-
formed both the quality control and meta-analyses for the
whole GWAS. A quality control protocol was set up that
included validation of the results file format, reports for range
of values, and elimination of potential biases (i.e., extremely
large beta values or SEs). Files were cross-validated between
the 2 research centers after quality control and meta-analyses
to check for inconsistencies. SNPs with a MAF of 1%,
imputation quality of 0.30 (MACH program) or 0.40
(IMPUTE program) and beta values of 4 or 4, and SNPs
that were not available in 4 studies were excluded from
further analysis.
The significance threshold for claiming association was
determined considering the number of independent tests per-
formed. This number was estimated using a modification of the
simpleM algorithm (40) applied to the genotypes of the CEU
collection in HapMap. The modification consisted of replacing
the observed correlation matrix for the nearest positive semi-
definite matrix, as implemented in the R software package
corpcor (http://www.R-project.org), to correct for biases intro-
duced by missing genotypes. It was estimated that the number
of independent tests represented by these SNPs was 3,156 (see
Supplementary Table 2, available on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.38300/abstract). The number of independent tests was used
to define a significance threshold of P  1.58  105,
according to Bonferroni multiplicity correction. No additional
correction was performed for stratification according to joint
and sex, because there is known heterogeneity across these
strata in OA genetics (2–5) and, therefore, no correction of this
type is used in OA genetic studies (6,8,9,11,13,14,16).
Results of the extension study were combined using a
Mantel-Haenszel approach (40). Combination of the extension
study data with the GWAS data was done using a fixed-effects
model with R software (http://www.R-project.org). Power es-
timates were obtained with Power and Sample Size software
(42). A full analysis of power is shown in Supplementary
Figure 1 (available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.38300/abstract).
For example, the power to detect association with a SNP of
MAF 20% and OR 1.15 for knee OA or 1.16 for hip OA was
80%, assuming no heterogeneity between the GWAS.
RESULTS
Systematic identification of candidate genes. A
total of 199 genes (Figure 1) have been investigated for
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their association with OA in humans, according to the
HuGe Navigator (35). The HuGe Navigator included
542 bibliographic references for the genetic studies of
the candidate genes. Some of the genes are from loci
that were associated with OA for the first time in GWAS
(HLA class II/III, A2BP1, and LCRH1) or in genome-
wide linkage studies (MATN3, DIO2, FRZB, and BMP5).
These genes were included because the identification of
many of them as putative susceptibility genes partially
came from post hoc analyses of their potential biologic
role, and because none has reached a genome-wide
significant association in Europeans. The 199 genes were
grouped in 158 nonoverlapping genome segments that
contained 27,501 autosomal SNPs (MAF of 5%) with
known genotypes in the CEU (Utah residents with
ancestry from northern and western Europe) population
of HapMap.
Meta-analysis of association of all SNPs in the
candidate genes. The effect sizes for each of the
9 GWAS corresponding to SNPs in the candidate genes
were obtained and combined in a meta-analysis. Geno-
types were available for 25,839 of the 27,501 SNPs
included in candidate genes after applying quality con-
trol filters (association results are available from the
corresponding author). These genotypes had been di-
rectly typed or imputed. No significant associations were
observed in the knee OA meta-analysis.
Meta-analysis of hip OA GWAS showed sig-
nificant association at 2 candidate genes. Two SNPs,
rs4907986 and rs1241164, in the 5 and 3 ends of
COL11A1, respectively, were associated in the unstrati-
fied analysis (Table 2 and Figure 2A). They comprised
2 independent associations, as manifested by the low
pairwise correlation coefficient (r2  0.09) between
them. A SNP of COL11A1, rs2615977, was highlighted
in the previously reported analysis of the arcOGEN
phase I study (with P  1.1  105) (23), which over-
laps with the current meta-analysis. However, none of
the 2 independent top associated SNPs showed strong
Figure 1. Osteoarthritis candidate genes selected from Human Ge-
nome Epidemiology Navigator.
Table 2. SNPs independently associated with hip osteoarthritis in all samples and in samples stratified
by sex*





rs4907986 1 103322221 T/C 1.12 (1.061.17) 1.29 105 0 0.63
rs1241164 1 103129065 T/C 0.82 (0.740.89) 1.47 105 0 0.92
Women
COL11A1
rs4908291 1 103345324 A/T 0.87 (0.820.92) 1.29 105 33.2 0.16
Men
VEGF
rs833058 6 43839832 T/C 0.85 (0.790.91) 1.35 105 18.6 0.29
* Single-nucleotide polymorphisms (SNPs) below the threshold of significance (P  1.58  105) are
shown. The odds ratios (ORs) and 95% confidence intervals (95% CIs) are relative to the first listed allele
at each SNP. Chr.  chromosome.
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correlation with rs2615977 (pairwise r2 0.4), and
rs2615977 was not among the most-associated SNPs in
the meta-analysis. An analysis stratified by sex also
showed association of COL11A1 SNP rs4908291 in
women. This SNP showed LD with rs4907986 (r2 0.68)
but not with rs1241164.
The second candidate gene associated with hip
OA was VEGF. Only a single SNP, rs833058, reached
association over the required threshold in men (Table
2). No other SNP with strong or modest (r2 0.5) LD
with rs833058 was observed in the meta-analysis (Figure
2B). None of the other 197 candidate genes showed
association with knee or with hip OA at the requested
level of significance.
Extension and summary studies. We attempted
to further establish the association of hip OA with
3 SNPs, 2 from COL11A1 representing the top SNPs of
the 2 independent associations in the combined analysis,
and the top SNP in VEGF. This part of the study was
not intended as a replication of the results due to the
relatively small number of independent samples that
were available.
For the COL11A1 SNPs, 1,929 samples from
Spanish and Greek individuals (787 patients with hip
OA and 1,142 control subjects) were studied. No signif-
icant association was observed in this underpowered
analysis; however, analysis of additional samples showed
independent association (Kerkhof HJM, van Meurs JB:
unpublished observations). In the combined analysis, the
significance of rs1241164 association was clearer (P 
5.3  106) than before, given that the direction of
change and effect size were similar in the meta-analysis
and the extension analysis (Table 3). The second signal,
corresponding to rs4907986, was slightly weakened in
the combined analysis, because the risk allele identified
in the meta-analysis showed the same direction only in
women in the extension study, not in men.
For VEGF SNP rs833058, we genotyped 5,921
additional individuals (3,303 patients with hip OA and
2,618 control subjects). No significant association was
observed in men (1,466 patients with hip OA and 1,263
control subjects), but the direction of change in the
extension study was the same as that in the meta-
analysis. Summary results in men showed association
slightly below that in the meta-analysis (2.6  105).
This SNP showed weak association in the combined
analysis of men and women in the extension study (P 
0.03).
DISCUSSION
This focused analysis of candidate genes within a
large meta-analysis of GWAS identified associations
Figure 2. Regional association plot showing the association of COL11A1 (A) and VEGF (B) loci with hip osteoarthritis. Each single-nucleotide
polymorphism (SNP) is shown as a diamond, located in the genome physical map (x-axis) and the –log10 scale of its P value of association (y-axis).
A, Pairwise correlation of each SNP with rs1241164, with white diamonds representing minimal correlation, blue diamonds representing maximal
correlation (r2 0.8), and magenta diamonds representing intermediate correlation (r2 0.50.8), and pairwise correlation of each SNP with
rs4907986, with white diamonds representing minimal correlation, red diamonds representing maximal correlation, and orange diamonds
representing intermediate correlation. B, Pairwise correlation of each SNP with the top associated SNP (rs833058), with white diamonds
representing minimal correlation and the red diamond representing maximal correlation. Dotted horizontal black lines show the 1.58  105
threshold for significance. Continuous blue lines represent the recombination rate (right y-axis).
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with hip OA in 2 genes: COL11A1, which showed
2 independent signals, and VEGF, which showed asso-
ciation in men. The main objective of the study was to
highlight SNPs for further study and confirmation as
new OA genetic factors. A secondary aim of the study
was to assess the validity of the candidate gene approach
in the study of OA. In this respect, we observed that
none of the other 197 candidate genes showed associa-
tion in our meta-analysis of GWAS.
Discovery of genetic associations has been greatly
advanced by GWAS due to increased sample sizes,
increased coverage of analyzed SNPs, and increases in
quality control standards and in the requirements to
claim association that have accompanied them. These
positive characteristics of the GWAS are further poten-
tiated by their combination through meta-analysis (17).
The current meta-analysis had an unprecedented power
to analyze most of the candidate genes (at least for an
OR of 1.15 and allele frequencies of 0.2), and
GWAS plus imputation provided very complete cover-
age of genetic variation in them.
In addition, focused analysis of candidate genes
should increase the chances of uncovering associations
worth pursuing, by the following 2 mechanisms: in-
creased prior likelihood of association and more tolerant
threshold to claim association (18,19). A series of studies
of other diseases have capitalized on the first mecha-
nism, either by considering candidate genes from previ-
ous genetic studies, as was done here, or by defining a set
of genes of high relevance for the disease, using biblio-
graphic analysis. The second mechanism, a more toler-
ant threshold for association, is related to a problem that
affects all complex diseases: the effect sizes of most
genetic factors are below an OR of 1.20, and therefore
large sample sizes are required to identify association at
the genome level. In this context, the use of focused
analysis in a subset of genes allows the selection of SNPs
not reaching genome-wide significance for further vali-
dation.
Another point that deserves comment is that
small variations between sample collections result in
large differences in statistical power. This is attributable
to the low effect sizes of most genetic factors and the
dramatic decrease in statistical power when the effect
size approaches 1.0 (see Supplementary Figure 1 avail-
able on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38300/abstract).
It is very likely that this extreme sensitivity to variation
of the effect size in the 1.0–1.15 range explains why
confirmed genetic factors fail to show significant associ-
ation even in some large studies, given that they are not
large enough to offset these small fluctuations. In addi-
tion, there is a dramatic decrease in power for SNPs with
a low MAF (10%) (Supplementary Figure 1). Thus,
we cannot exclude the possibility that some additional
Table 3. Association of the 2 top independent SNPs in COL11A1 and the top SNP in VEGF with
hip OA*
GWAS meta-analysis Extension study
GWAS meta-analysis plus
extension study
Gene, SNP, sex ORM-H (95% CI) P ORM-H (95% CI) P OR (95% CI) P
COL11A1
rs1241164
All 0.82 (0.74–0.89) 1.47 105 0.85 (0.68–1.06) 0.15 0.82 (0.75–0.89) 5.3 106
Female 0.79 (0.7–0.89) 1.27 104 0.96 (0.70–1.32) 0.81 0.81 (0.72–0.91) 2.4 104
Male 0.84 (0.74–0.97) 0.012 0.77 (0.56–1.06) 0.11 0.83 (0.73–0.94) 3.7 103
rs4907986
All 1.12 (1.06–1.17) 1.29  105 0.98 (0.85–1.12) 0.77 1.09 (1.05–1.15) 5.8 105
Female 1.13 (1.07–1.21) 1.05 104 1.15 (0.95–1.39) 0.13 1.13 (1.07–1.21) 3.2 105
Male 1.1 (1.03–1.19) 0.0069 0.95 (0.77–1.18) 0.67 1.08 (1.01–1.16) 0.015
VEGF
rs833058
All 0.92 (0.88–0.97) 0.0022 0.92 (0.85–0.99) 0.03 0.92 (0.88–0.96) 1.9 104
Female 0.99 (0.93–1.06) 0.75 0.91 (0.81–1.01) 0.07 0.97 (0.91–1.02) 0.21
Male 0.85 (0.79–0.91) 1.3 105 0.94 (0.84–1.06) 0.31 0.87 (0.82–0.93) 2.6 105
* Single-nucleotide polymorphisms (SNPs) rs1241164 and rs4907986 were genotyped only in samples from
Spain and Greece. The odds ratios (ORs) and 95% confidence intervals (95% CIs) are relative to the first
listed allele for each SNP in Table 2. OA  osteoarthritis; GWAS  genome-wide association study;
ORM-H  OR as determined using the Mantel-Haenszel approach. No significant heterogeneity
(P  0.05) was detected in any of the combined analyses.
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candidate genes may have associations with OA with an
OR of 1.10 or if their minor allele frequencies are low.
COL11A1 codes for a minor component of the
cartilage matrix, the importance of which has been
shown by the chondrodysplasia mouse mutation, the
skeletal abnormalities of Stickler syndrome, type II
(OMIM ID 604841) and Marshall syndrome (OMIM ID
154780), and mutations in patients with fibrochondro-
genesis and by association with susceptibility to lumbar
disc herniation (http://omim.org/entry/120280). The 2 top
SNPs associated with OA in our analysis were indepen-
dent and different from those observed in a previous OA
study (23). This raises the possibility of multiple variants
with an effect in OA susceptibility.
VEGF was associated with hip OA only in men,
according to our meta-analysis. This gene codes for a
very important angiogenic factor that is involved in
normal growth plate development, endochondral ossifi-
cation, and articular cartilage formation (43). It is one of
the overexpressed markers of hypertrophic chondro-
cytes. It contributes to OA changes in animal models by
stimulating chondrocyte proliferation, apoptosis, and
production of catabolic mediators (44). Although it has
been considered an OA candidate gene, no previous
study showed significant association.
For the remaining candidate genes, we did not
observe association in spite of the large number of
samples assembled (the largest ever studied for most
candidate genes) and the more tolerant threshold for
significance allowed by the focused analysis. This does
not exclude SNPs of weak effect or those showing
heterogeneity between the sample collections. Also, it is
possible that some gene variants were not adequately
covered, especially those with low frequency or multi-
allelic polymorphisms, as in ASPN (45) or BMP5
(46,47). Other reported associations have been de-
scribed as specific for an OA subphenotype not included
in our meta-analysis, such as the association of MATN3
with OA in the first carpometacarpal joint (48) or
DIO2 in women with severe OA (49). In addition,
GDF5, which has been also a candidate gene, was not
included in this analysis because it is already confirmed
as an OA susceptibility locus at the genome-wide sig-
nificance level (6,7).
All of the previous caveats apply, but they do not
negate the conclusion of a general lack of reproducibility
of OA candidate genes. This is particularly true for
genes highlighted in candidate gene studies of small size
and showing large effect sizes. It has become clear that
the effect sizes and ORs reported were widely overesti-
mated, because we would have observed most associa-
tions with ORs 1.20, and most reported ORs in these
studies were 2-fold. Our findings suggest that tradi-
tionally conducted candidate gene studies are unlikely to
be fruitful in OA genetics. However, such candidate
gene studies are likely to continue to be useful to
validate or refine loci from hypothesis-free genome-wide
studies.
In summary, our candidate gene meta-analysis of
9 OA GWAS highlighted the association of COL11A1
and VEGF with hip OA and showed a lack of association
for the other 197 candidate genes.
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